Format

Send to

Choose Destination
Eur Urol. 2017 Oct;72(4):477-481. doi: 10.1016/j.eururo.2017.03.047. Epub 2017 Apr 14.

Immune Checkpoint Inhibition in Metastatic Urothelial Cancer.

Author information

1
Barts Cancer Institute, London, UK. Electronic address: thomas.powles@bartshealth.nhs.uk.
2
Barts Cancer Institute, London, UK.
3
Department of Urology, University of Tübingen, Tübingen, Germany.
4
Department of Urology, University of Tübingen, Tübingen, Germany. Electronic address: jens.bedke@med.uni-tuiebingen.de.

Abstract

Immune checkpoint inhibitors are a new treatment option in metastatic urothelial cancer on the basis of available phase 2 and 3 trials. Predictive biomarkers are needed. These should go beyond PD-L1 expression, which is showing inconsistent results across trials.

PMID:
28413128
DOI:
10.1016/j.eururo.2017.03.047
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center